Quote:

---

In again reviewing Dr Jay's shareholder letter and related info, I took particular note of his observation that oncology holds "the highest potential and shortest timeline for return on investment in the form of a partnership or drug approval."

---

If the entity paying for the Alzheimer's study is willing to fund a properly sized phase 2 trial, It will be a tossup which can get approval first. With the FDA willing to approve drugs that show little to no improvement in Alzheimer's they will approve a drug with compelling evidence from a phase 2. With the clamor that aduhelm got from patient advocates can you imagine the outcry for a drug that actually works.